These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 26362898)

  • 21. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.
    Molyneux PD; Barker GJ; Barkhof F; Beckmann K; Dahlke F; Filippi M; Ghazi M; Hahn D; MacManus D; Polman C; Pozzilli C; Kappos L; Thompson AJ; Wagner K; Yousry T; Miller DH;
    Neurology; 2001 Dec; 57(12):2191-7. PubMed ID: 11756596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
    Neurology; 1993 Apr; 43(4):655-61. PubMed ID: 8469318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Limited effect of interferon-beta for the treatment of secondary progressive multiple sclerosis].
    Schreiber K; Voldsgaard A; Sørensen PS
    Ugeskr Laeger; 2013 May; 175(19):1342-4. PubMed ID: 23663372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
    Goodin DS; Traboulsee A; Knappertz V; Reder AT; Li D; Langdon D; Wolf C; Beckmann K; Konieczny A; Ebers GC;
    J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):282-7. PubMed ID: 22193561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EDSS variability before randomization may limit treatment discovery in primary progressive MS.
    Zhang J; Waubant E; Cutter G; Wolinsky JS; Glanzman R
    Mult Scler; 2013 May; 19(6):775-81. PubMed ID: 23027880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.
    Molyneux PD; Kappos L; Polman C; Pozzilli C; Barkhof F; Filippi M; Yousry T; Hahn D; Wagner K; Ghazi M; Beckmann K; Dahlke F; Losseff N; Barker GJ; Thompson AJ; Miller DH
    Brain; 2000 Nov; 123 ( Pt 11)():2256-63. PubMed ID: 11050025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.
    Kobelt G; Jönsson L; Miltenburger C; Jönsson B
    Int J Technol Assess Health Care; 2002; 18(1):127-38. PubMed ID: 11987436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.
    Barkhof F; van Waesberghe JH; Filippi M; Yousry T; Miller DH; Hahn D; Thompson AJ; Kappos L; Brex P; Pozzilli C; Polman CH;
    Brain; 2001 Jul; 124(Pt 7):1396-402. PubMed ID: 11408334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta.
    Galassi S; Prosperini L; Logoteta A; Hirsch MN; Fanelli F; De Giglio L; Pozzilli C
    Mult Scler Relat Disord; 2016 Jul; 8():99-106. PubMed ID: 27456883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon β for secondary progressive multiple sclerosis: a systematic review.
    La Mantia L; Vacchi L; Rovaris M; Di Pietrantonj C; Ebers G; Fredrikson S; Filippini G
    J Neurol Neurosurg Psychiatry; 2013 Apr; 84(4):420-6. PubMed ID: 22952326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS.
    Inglese M; van Waesberghe JH; Rovaris M; Beckmann K; Barkhof F; Hahn D; Kappos L; Miller DH; Polman C; Pozzilli C; Thompson AJ; Yousry TA; Wagner K; Comi G; Filippi M
    Neurology; 2003 Mar; 60(5):853-60. PubMed ID: 12629246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.
    Kappos L; Edan G; Freedman MS; Hartung HP; Montalbán X; Barkhof F; Koelbach R; MacManus DG; Wicklein EM;
    J Neurol; 2024 Jul; 271(7):4599-4609. PubMed ID: 38730097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis.
    Touchette DR; Durgin TL; Wanke LA; Goodkin DE
    Clin Ther; 2003 Feb; 25(2):611-34. PubMed ID: 12749517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
    Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T
    JAMA Neurol; 2019 Mar; 76(3):274-281. PubMed ID: 30615019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study.
    Patti F; Penaherrera JN; Zieger L; Wicklein EM
    BMC Neurol; 2021 Aug; 21(1):324. PubMed ID: 34425763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon beta in secondary progressive multiple sclerosis : daily clinical practice.
    Río J; Tintoré M; Nos C; Téllez N; Galán I; Pelayo R; Montalban X
    J Neurol; 2007 Jul; 254(7):849-53. PubMed ID: 17361342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical characteristics of responders to interferon therapy for relapsing MS.
    Waubant E; Vukusic S; Gignoux L; Dubief FD; Achiti I; Blanc S; Renoux C; Confavreux C
    Neurology; 2003 Jul; 61(2):184-9. PubMed ID: 12874396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting the severity of relapsing-remitting MS: the contribution of cross-sectional and short-term follow-up MRI data.
    Enzinger C; Fuchs S; Pichler A; Wallner-Blazek M; Khalil M; Langkammer C; Ropele S; Fazekas F
    Mult Scler; 2011 Jun; 17(6):695-701. PubMed ID: 21228028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.